Shandong Sinobioway Biomedicine Valuation

Is 002581 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002581 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 002581's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 002581's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002581?

Key metric: As 002581 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 002581. This is calculated by dividing 002581's market cap by their current revenue.
What is 002581's PS Ratio?
PS Ratio	19.3x
Sales	CN¥406.15m
Market Cap	CN¥7.84b

002581 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	18.5x
Enterprise Value/EBITDA	-193x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 002581's PS Ratio compare to its peers?

The above table shows the PS ratio for 002581 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.6x
300723 ApicHope Pharmaceutical	3.9x	21.7%	CN¥7.4b
601089 Beijing Foyou PharmaLTD	2.1x	n/a	CN¥7.3b
600252 Guangxi Wuzhou Zhongheng GroupLtd	2.9x	n/a	CN¥8.4b
600195 China Animal Husbandry Industry	1.3x	12.5%	CN¥7.0b
002581 Shandong Sinobioway Biomedicine	19.3x	n/a	CN¥7.8b

Price-To-Sales vs Peers: 002581 is expensive based on its Price-To-Sales Ratio (19.3x) compared to the peer average (2.6x).

Price to Sales Ratio vs Industry

How does 002581's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.28b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$758.85m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$399.69m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 002581 is expensive based on its Price-To-Sales Ratio (19.3x) compared to the CN Pharmaceuticals industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is 002581's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002581 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	19.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 002581's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.19

-2.6%

13.6%